Caris expands its extensive network of leading cancer institutions committed to improving patient outcomes through innovations in precision medicine
IRVING, Texas, May 31, 2023 – Caris Life Sciences® (Caris), the leading molecular science and technology company actively developing and delivering innovative solutions to revolutionize healthcare, announced today that Memorial Sloan Kettering Cancer Center (MSK), one of the world’s premier cancer centers, has joined the Caris Precision Oncology Alliance™ (POA) and will collaborate with Caris on various research projects.
The POA is a growing network of leading cancer centers across the globe that collaborate to advance precision oncology and biomarker-driven research, with its members working together to establish and optimize standards of care for molecular testing through innovative research to improve clinical outcomes for cancer patients. POA members are uniquely positioned to leverage Caris’ highly sophisticated AI bioinformatics and machine learning capabilities across the company’s massive clinico-genomic database to enable innovative research to improve clinical outcomes for cancer patients.
“As one of the world’s most respected comprehensive centers devoted exclusively to cancer, we are thrilled to welcome MSK to the Caris Precision Oncology Alliance which is uniquely positioned to leverage precision oncology research to improve the outcomes of all patients suffering from cancer,” said Chadi Nabhan, M.D., MBA, FACP, SVP and Chairman of the Caris POA.
As a POA member, MSK will collaborate with Caris on various research projects, including a pilot project to validate a signature that potentially predicts the development of brain metastases in patients with solid malignancies.
“We’re excited to collaborate with Caris as a member of the POA,” said Luke Pike, M.D., Ph.D., Assistant Attending in Radiation Oncology at MSK. “More than 200,000 Americans are diagnosed with brain metastasis every year and yet we know very little about why this happens or the biology of cancers once they have spread to the brain. Our hope is that our joint project will fundamentally improve our understanding of the mechanistic underpinnings of brain metastasis and help us predict which patients are at highest risk for this terrible affliction.”
The Caris Precision Oncology Alliance includes 85 cancer centers and academic institutions. These institutions have early access to the extensive database and artificial intelligence platform within Caris to establish evidence-based standards for cancer profiling and molecular testing in oncology. By leveraging the comprehensive genomic, transcriptomic and proteomic profiling available through Caris molecular profiling, Caris seeks to provide this network with the ability to prioritize therapeutic options and determine which clinical trial opportunities may benefit their patients. POA members are also able to integrate with a growing portfolio of biomarker-directed trials sponsored by biopharma. Additionally, POA member institutions have access to the most comprehensive clinico-genomic database in the industry, which includes matched molecular and clinical outcomes data from more than 390,000 patients, covering over 1 million data points per patient.
About Caris Life Sciences
Caris Life Sciences® (Caris) is the pioneer in precision medicine and leading molecular science and technology company actively developing and delivering innovative solutions to revolutionize healthcare and improve patient outcomes. Through comprehensive molecular profiling (Whole Exome and Whole Transcriptome Sequencing) and the application of advanced artificial intelligence (AI) and machine learning algorithms, Caris has created the large-scale clinico-genomic database and cognitive computing needed to analyze and unravel the molecular complexity of disease. This convergence of data and machine learning provides an unmatched resource and the ideal path forward to conduct the basic, fundamental research to accelerate discovery for detection, diagnosis, monitoring, therapy selection and drug development to improve the human condition.
With a primary focus on cancer, Caris’ suite of market-leading molecular profiling offerings assesses DNA, RNA and proteins to reveal a molecular blueprint that helps patients, physicians and researchers better detect, diagnose and treat patients. The company’s latest advancement, Caris Assure™, is a blood-based, circulating nucleic acids sequencing (cNAS) assay that combines comprehensive molecular analysis (Whole Exome and Whole Transcriptome Sequencing from blood) and serial monitoring – making it the most powerful liquid biopsy assay ever developed.
Headquartered in Irving, Texas, Caris has offices in Phoenix, New York, Tokyo, Japan and Basel, Switzerland. Caris or its distributors provide services in the U.S., Europe, Asia and other international markets. To learn more, please visit CarisLifeSciences.com or follow us on LinkedIn.